Published On: Thu, Sep 14th, 2017

Cell Therapeutics, Inc. (CTIC) – Brokers Update Their Views


A number of investment brokers have recently updated their price targets on shares of Cell Therapeutics, Inc. (CTIC).

Most recent broker ratings

09/12/2017 – Jefferies began new coverage on Cell Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 7.5 price target on the stock.

08/29/2016 – Cell Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 0.75 price target on the stock.

02/10/2016 – Cell Therapeutics, Inc. was downgraded to “neutral” by analysts at Ladenburg Thalmann.

02/10/2016 – Cell Therapeutics, Inc. was downgraded to “sell” by analysts at WallachBeth Capital.

08/12/2015 – Cell Therapeutics, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 4.5 price target on the stock.

06/01/2015 – Cell Therapeutics, Inc. had its “fair value” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 1.94 price target on the stock.

05/18/2015 – Cell Therapeutics, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 2 price target on the stock.

05/08/2015 – Cell Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 4 price target on the stock.

02/03/2014 – Cell Therapeutics, Inc. was upgraded to “buy” by analysts at Thomson Reuters/Verus.

10/07/2013 – Cell Therapeutics, Inc. had its “positive” rating reiterated by analysts at Wells Fargo.

The share price of Cell Therapeutics, Inc. (CTIC) was up +0.00% during the last day of trading, with a day high of 3.35. 435181 shares were traded during the last session.

The stock’s 50 day moving average is 3.34 and its 200 day moving average is 3.77. The stock’s market capitalization is 104.38M. Cell Therapeutics, Inc. has a 52-week low of 0.36 and a 52-week high of 6.48.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.